Open Label Randomized Phase II Trial of Nivolumab + Cabiralizumab (BMS-986227, FPA008) + Gemcitabine in Patients With Stage IV Pancreatic Cancer Achieving Disease Control in Response to First-line Chemotherapy (GemCaN Trial)
Status: Not yet recruiting
Phase of Trial: Phase II
Latest Information Update: 08 May 2019
Price : $35 *
At a glance
- Drugs Cabiralizumab (Primary) ; Gemcitabine (Primary) ; Nivolumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- Acronyms GemCaN Trial
- 02 May 2019 Planned initiation date changed from 1 Jul 2019 to 1 Sep 2019.
- 07 Jan 2019 Planned End Date changed from 1 Oct 2020 to 1 Dec 2021.
- 07 Jan 2019 Planned primary completion date changed from 1 Oct 2020 to 1 Dec 2021.